var data={"title":"Carmustine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carmustine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5828?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carmustine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carmustine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=carmustine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Carmustine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708652\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myelosuppression (injection)</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections. Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose. Do not administer a repeat course of carmustine until blood counts recover.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pulmonary toxicity (injection)</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine causes dose-related pulmonary toxicity. Patients receiving greater than 1,400 mg/m<sup>2</sup> cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in childhood.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146512\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BiCNU;</li>\n      <li>Gliadel Wafer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146513\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>BiCNU;</li>\n      <li>Gliadel Wafer</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146552\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Alkylating Agent;</li>\n      <li>\n        Antineoplastic Agent, Alkylating Agent (Nitrosourea)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146516\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Carmustine (IV) is associated with a moderate to high emetic potential (dose-related); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Brain tumors, Hodgkin lymphoma, multiple myeloma, non-Hodgkin lymphoma:</b> <i>Manufacturer&rsquo;s labeling:</i> IV: 150 to 200 mg/m<sup>2</sup> every 6 weeks or 75 to 100 mg/m<sup>2</sup>/day for 2 days every 6 weeks (as a single agent in previously untreated patients; lower doses are used in combination with other chemotherapy agents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glioblastoma multiforme (recurrent), glioma (malignant, newly-diagnosed high-grade):</b> Implantation (wafer): 8 wafers (7.7 mg each) implanted intracranially into in the resection cavity (total dose 61.6 mg); should the size and shape not accommodate 8 wafers, the maximum number of wafers feasible (up to 8) should be placed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Indication-specific dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Brain tumor, primary (off-label doses):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">80 mg/m<sup>2</sup>/day for 3 days every 8 weeks for 6 cycles (Brandes 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">200 mg/m<sup>2</sup> every 8 weeks [maximum cumulative dose: 1,500 mg/m<sup>2</sup>] (Selker 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma, relapsed or refractory (off-label dose):</b> IV: Mini-BEAM regimen: 60 mg/m<sup>2</sup> day 1 every 4 to 6 weeks (in combination with etoposide, cytarabine, and melphalan) (Colwill 1995; Martin 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple myeloma, relapsed, refractory (off-label dose):</b> IV: VBMCP regimen: 20 mg/m<sup>2</sup> day 1 every 35 days (in combination with vincristine, melphalan, cyclophosphamide, and prednisone) (Kyle 2006; Oken 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mycosis fungoides, early stage (off-label use) (Zackheim 2003):</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment (10 mg/100 grams petrolatum): Apply (with gloves) once daily to affected areas. Additional data may be necessary to further define the role of carmustine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution (0.2% solution in alcohol; dilute 5 mL in 60 mL water): Apply (with gloves) once daily to affected areas. Additional data may be necessary to further define the role of carmustine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stem cell or bone marrow (autologous) transplant conditioning regimen (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BEAM regimen: 300 mg/m<sup>2</sup> as a single dose 6 days prior to transplant (in combination with etoposide, cytarabine, and melphalan) (Chopra 1993; Linch 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CBV regimen: 600 mg/m<sup>2</sup> as a single dose 3 days prior to transplant (in combination with cyclophosphamide and etoposide) (Reece 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50023578\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=carmustine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Carmustine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Carmustine (IV) is associated with a moderate to high emetic potential (dose-related); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stem cell or bone marrow transplant (autologous) myeloablative conditioning regimen for relapsed or refractory Hodgkin or non-Hodgkin lymphoma (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BEAM regimen:</i> Adolescents &ge;15 years: IV: 300 mg/m<sup>2 </sup>as a single dose 6 days prior to transplant (in combination with etoposide, cytarabine, and melphalan) (Chopra 1993; Mills 1995). Additional data may be necessary to further define the role of carmustine in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CBV regimen:</i> Children and Adolescents: IV: 100 mg/m<sup>2</sup> once daily for 3 days beginning 8 days prior to transplant (in combination with cyclophosphamide and etoposide) (Harris 2011). Additional data may be necessary to further define the role of carmustine in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146517\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426174\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Manufacturer&rsquo;s labeling: CrCl &lt;10 mL/minute: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The following dosage adjustments have also been reported (Kintzel 1995):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 46 to 60 mL/minute: Reduce dose to 80% of the usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 31 to 45 mL/minute: Reduce dose to 75% of the usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute: Consider use of alternative drug.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wafer implant: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146518\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">IV and wafer implant: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344387\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (<b>Note:</b> Excludes HSCT dosing):</i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of body surface area in carmustine dosing for hematopoietic stem cell transplant conditioning regimens in adult patients weighing &le;120% of their ideal body weight (IBW). In patients weighing &gt;120% IBW, utilize adjusted body weight 25% (ABW25) to calculate BSA (Bubalo 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ABW25: Adjusted wt (kg) = Ideal body weight (kg) + 0.25 [actual wt (kg) - ideal body weight (kg)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12855270\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hematologic toxicity:</b> Based on nadir counts with previous dose (manufacturer&rsquo;s labeling). IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If leukocytes &ge;3,000/mm<sup>3</sup> and platelets &ge;75,000/mm<sup>3</sup>: Administer 100% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If leukocytes 2,000 to 2,999/mm<sup>3</sup> or platelets 25,000 to 74,999/mm<sup>3</sup>: Reduce dose to 70% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If leukocytes &lt;2,000/mm<sup>3</sup> or platelets &lt;25,000/mm<sup>3</sup>: Reduce dose to 50% of usual dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146489\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BiCNU: 100 mg (1 ea) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Wafer, Implant: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gliadel Wafer: 7.7 mg (8 ea) [contains polifeprosan 20]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146473\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146492\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine (IV) is associated with a moderate to high emetic potential (dose-related); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Infuse slowly over at least 2 hours (infusions &lt;2 hours may lead to injection site pain or burning); infuse through a free-flowing saline or dextrose infusion, or administer through a central catheter to alleviate venous pain/irritation. Do not exceed a rate of 1.66 mg/m<sup>2</sup>/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Irritant; infiltration may result in local pain, erythema, swelling, burning and skin necrosis; the alcohol-based diluent may be an irritant, especially with high doses. Avoid extravasation. Monitor infusion site.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High-dose carmustine (transplant dose; off-label use): Infuse over a least 2 hours to avoid excessive flushing, agitation, and hypotension; was infused over 1 hour in some trials (Chopra 1993). <b>High-dose carmustine may be fatal if not followed by stem cell rescue.</b> Monitor vital signs frequently during infusion; patients should be supine during infusion and may require the Trendelenburg position, fluid support, and vasopressor support.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Implant: Double glove before handling; outer gloves should be discarded as chemotherapy waste after handling wafers. Any wafer or remnant that is removed upon repeat surgery should be discarded as chemotherapy waste. The outer surface of the external foil pouch is not sterile. Open pouch gently; avoid pressure on the wafers to prevent breakage. Wafers that are broken in half may be used, however, wafers broken into more than 2 pieces should be discarded in a biohazard container. Slight overlapping of wafers during placement is acceptable. Oxidized regenerated cellulose (Surgicel) may be placed over the wafer to secure; irrigate cavity prior to closure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical (off-label use): Apply solution with brush or gauze pads; ointment and solution should be applied while wearing gloves to involved areas only; avoid contact with eyes or mouth (Zackheim 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130925\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (if applicable) closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146490\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain tumors:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection: Palliative treatment of brain tumors including glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Wafer (implant): Treatment of newly-diagnosed high-grade malignant glioma (as an adjunct to surgery and radiation); treatment of recurrent glioblastoma multiforme (as adjunct to surgery)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hodgkin lymphoma, relapsed/refractory:</b> Injection: Palliative treatment (secondary) of Hodgkin lymphoma (in combination with other antineoplastics) that has relapsed with or was refractory to primary therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Multiple myeloma:</b> Injection: Palliative treatment of multiple myeloma (in combination with prednisone)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Non-Hodgkin lymphomas, relapsed/refractory:</b> Injection: Palliative treatment (secondary) of non-Hodgkin lymphoma (in combination with other antineoplastics) that has relapsed with or was refractory to primary therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722051\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Mycosis fungoides (topical); Stem cell or bone marrow transplant (autologous) conditioning regimen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2136823\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carmustine may be confused with bendamustine, lomustine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146481\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Implant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Seizure (37%; new or worsening: 20%), cerebral edema (4% to 23%), depression (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash (5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Nausea (22%), vomiting (21%), constipation (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Urinary tract infection (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Weakness (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Wound healing impairment (14% to 16%), fever (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Chest pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Intracranial hypertension (9%), cerebral hemorrhage (6%), meningitis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Abdominal pain (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Abscess (local 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Back pain (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV:</b> Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, flushing (with rapid infusion), occlusive arterial disease, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Brain disease, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, burning sensation of skin, hyperpigmentation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Gynecomastia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Acute leukemia, anemia, bone marrow dysplasia, leukemia, leukopenia (common; onset: 5 to 6 weeks; recovery: after 1 to 2 weeks), thrombocytopenia (common: onset: ~4 weeks; recovery: after 1 to 2 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Opportunistic infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Burning sensation at injection site, erythema at injection site, pain at injection site, swelling at injection site, tissue necrosis at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, conjunctival edema, conjunctival hemorrhage, ophthalmic signs and symptoms (loss of depth perception), suffusion of the conjunctiva (with rapid infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Azotemia (progressive), nephron atrophy, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Interstitial pulmonary disease, pneumonitis, pulmonary fibrosis (occurring up to 17 years after treatment), pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Febrile neutropenia (Chopra 1993), sepsis (implant), venous thrombosis at injection site (IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146495\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Hypersensitivity to carmustine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Implant: There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146477\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Carmustine IV causes bone marrow suppression, primarily thrombocytopenia (which may lead to bleeding) and leukopenia (which may cause infection). Monitor blood counts weekly for at least 6 weeks following each dose. Adjust dosage based on nadir blood counts from prior dose for dosage adjustment. Do not administer a repeat course until blood counts recover.</b> Hematologic toxicity is dose-limiting, may be severe, and is generally delayed and cumulative; thrombocytopenia is usually more severe than leukopenia. Myelosuppression generally occurs 4 to 6 weeks after administration; thrombocytopenia occurs at ~4 weeks and persists for 1 to 2 weeks; leukopenia occurs at 5 to 6 weeks and persists for 1 to 2 weeks. Anemia may occur (less common and less severe than leukopenia or thrombocytopenia). Platelet counts should be &gt;100,000/mm<sup>3</sup> and leukocytes should be &gt;4,000/mm<sup>3</sup> prior to a repeat course (repeat courses should not be administered more frequently than every 6 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Carmustine IV is associated with a moderate to high emetic potential (dose-related); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic: Reversible increases in transaminases, bilirubin, and alkaline phosphatase have been reported (rare) with the IV formulation. Monitor liver function tests periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-site reactions: Rapid infusions are associated with skin flushing and suffusion of the conjunctiva (onset: &lt;2 hours; duration ~4 hours). Carmustine is also associated with injection-site burning and local tissue reactions, including swelling, pain, erythema, and necrosis, have been reported. Monitor infusion site closely for infiltration or injection-site reactions. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intracranial hypertension: Brain edema has been reported in patients with newly diagnosed glioma receiving wafer implants, including one report of intracranial mass effect unresponsive to corticosteroids that led to brain herniation. Monitor closely for intracranial hypertension related to brain edema, inflammation, or necrosis of brain tissue surrounding resection. Re-operation to remove wafers (or remnants) may be necessary for refractory cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningitis: Cases of meningitis have occurred in patients with recurrent glioma receiving wafer implants. Two cases were bacterial (one patient required removal of implants 4 days after implantation and the other developed meningitis following reoperation for recurrent tumor). Another case was determined to be chemical meningitis and resolved with corticosteroids. Monitor postoperatively for signs/symptoms of meningitis and CNS infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Investigational administration (intraarterial intracarotid route [not an approved route]) has been associated with ocular toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: <b>[US Boxed Warning]: Carmustine IV is associated with dose-related pulmonary toxicity; patients receiving cumulative doses &gt;1,400 mg/m<sup>2</sup> are at significantly higher risk. Delayed onset of pulmonary fibrosis may occur years after treatment (may be fatal), particularly in children.</b> Pulmonary toxicity has occurred in children and adolescents up to 17 years after treatment; this occurred in ages 1 to 16 for the treatment of intracranial tumors; cumulative doses ranged from 770 to 1,800 mg/m<sup>2</sup> (in combination with cranial radiotherapy). Pulmonary toxicity is characterized by pulmonary infiltrates and/or fibrosis and has been reported from 9 days to 43 months after nitrosourea treatment (including carmustine). Although pulmonary toxicity generally occurs in patients who have received prolonged treatment, pulmonary fibrosis has been reported with cumulative doses below 1,400 mg/m<sup>2</sup>. Interstitial fibrosis at lower doses has occurred (rare). In addition to high cumulative doses, other risk factors for pulmonary toxicity include history of lung disease and baseline predicted forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) &lt;70%. Baseline and periodic pulmonary function tests are recommended. For high-dose treatment (transplant; off-label dose), acute lung injury may occur ~1 to 3 months post transplant; advise patients to contact their transplant physician for dyspnea, cough, or fever; interstitial pneumonia may be managed with a course of corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal: Renal failure, progressive azotemia, and decreased kidney size have been reported in patients who have received large cumulative IV doses or prolonged IV treatment. Renal toxicity has also been reported in patients who have received lower cumulative doses. Monitor renal function tests periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Long-term IV use is associated with the development of secondary malignancies (acute leukemias and bone marrow dysplasias).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures occurred in patients who received carmustine wafer implants, including new or worsening seizures and treatment-emergent seizures. Just over half of treatment-emergent seizures occurred within 5 days of surgery; the median onset of first new or worsened post-operative seizure was 4 days. Optimal anti-seizure therapy should be initiated prior to surgery. Monitor (postoperatively) for seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing impairment: Impaired neurosurgical wound healing, including would dehiscence, delayed healing, and subdural, subgleal or wound effusions may occur with carmustine wafer implant treatment; cerebrospinal fluid leaks have also been reported. Monitor post-operatively for impaired neurosurgical wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: May require dosage adjustment or discontinuation in patients with renal impairment. Do not administer carmustine IV in patients with compromised renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children are at higher risk of delayed pulmonary toxicity with the IV formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Diluent contains ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wafer: Monitor closely for known craniotomy-related complications (seizure, intracranial infection, abnormal wound healing, brain edema). Wafer migration may occur; avoid communication between the resection cavity and the ventricular system to prevent wafer migration; communications larger than the wafer should be closed prior to implantation; wafer migration into the ventricular system may cause obstructive hydrocephalus. Monitor for signs/symptoms of obstructive hydrocephalus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298978\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146483\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9206&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May enhance the myelosuppressive effect of Carmustine. Management: Consider alternatives to cimetidine in patients receiving carmustine.  If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melphalan: May enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146485\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146498\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on the mechanism of action, carmustine may cause fetal harm if administered to a pregnant woman. Females of reproductive potential should use highly effective contraceptives during and for at least 6 months following treatment. Males of reproductive potential should use highly effective contraceptives during and for at least 3 months following treatment. May impair male fertility. Advise males of potential risk of infertility and to seek fertility/family planning counseling prior to receiving carmustine wafer implants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146499\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if carmustine is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends breastfeeding be discontinued during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146487\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: CBC with differential and platelet count (weekly for at least 6 weeks after a dose), pulmonary function tests (FVC, DL<sub>CO</sub>; at baseline and frequently during treatment), liver function (periodically), renal function tests (periodically); monitor blood pressure and vital signs during administration, monitor infusion site for possible infiltration; monitor for signs/symptoms of pulmonary toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Wafer: Monitor postoperatively for seizures, impaired neurosurgical wound healing, and signs/symptoms of meningitis, CNS infection, and obstructive hydrocephalus; monitor closely for intracranial hypertension related to brain edema, inflammation, or necrosis of brain tissue surrounding resection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146476\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Carmustine interferes with the normal function of DNA and RNA by alkylation and cross-linking the strands of DNA and RNA, and by possible protein modification; may also inhibit enzyme processes by carbamylation of amino acids in protein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146494\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: 3.3 L/kg; readily crosses blood-brain barrier producing CSF levels &ge;50% of blood plasma levels; highly lipid soluble</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapidly hepatic; forms active metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: 15 to 75 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: IV: Urine (~60% to 70%) within 96 hours; lungs (~10% as CO<sub>2</sub>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5100296\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (BiCNU Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $4,716.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Wafer</b> (Gliadel Wafer Implant)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.7 mg (8): $36,583.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146500\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bcnu (BG, HN);</li>\n      <li>Becenun (BR, FI, NO);</li>\n      <li>BiCNU (AR, CO, CZ, FR, GB, IE, KR, MX, NZ, PH, PT, TW, UY, ZA);</li>\n      <li>BICNU (BB, EC, VN);</li>\n      <li>Bicnu (CL, HU);</li>\n      <li>Carmubris (AT, DE);</li>\n      <li>Gliadel (GR, HK, IE, IL, IT, JP, MY, NL, SG, TH, TW);</li>\n      <li>Gliadel Implant (AU, ES);</li>\n      <li>Nitrumon (BE, LU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Benekli M, Smiley SL, Younis T, et al, &ldquo;Intensive Conditioning Regimen of Etoposide (VP-16), Cyclophosphamide and Carmustine (VCB) Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin's Lymphoma,&rdquo; <i>Bone Marrow Transplant</i>, 2008, 41(7):613-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/18071290/pubmed\" target=\"_blank\" id=\"18071290\">18071290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BiCNU (carmustine) [prescribing information]. Bristol Labs Oncology Prods; June 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BiCNU (carmustine) [prescribing information]. Eatontown, NJ: Heritage Pharmaceuticals; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brandes AA, Tosoni A, Amist&agrave; P, et al, &ldquo;How Effective is BCNU in Recurrent Glioblastoma in the Modern Era? A Phase II Trial,&rdquo; <i>Neurology</i>, 2004, 63(7):1281-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/15477552/pubmed\" target=\"_blank\" id=\"15477552\">15477552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8443375\"></a>Chopra R, McMillan AK, Linch DC, et al, &ldquo;The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients,&rdquo; <i>Blood</i>, 1993, 81(5):1137-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/8443375/pubmed\" target=\"_blank\" id=\"8443375\">8443375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colwill R, Crump M, Couture F, et al,, &ldquo;Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease Before Intensive Therapy and Autologous Bone Marrow Transplantation,&rdquo; <i>J Clin Oncol</i>, 1995, 13(2):396-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7844600/pubmed\" target=\"_blank\" id=\"7844600\">7844600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durando X, Lemaire JJ, Tortochaux J, et al, &ldquo;High-Dose BCNU Followed by Autologous Hematopoietic Stem Cell Transplantation in Supratentorial High-Grade Malignant Gliomas: A Retrospective Analysis of 114 Patients,&rdquo; <i>Bone Marrow Transplant</i>, 2003, 31(7):559-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/12692621/pubmed\" target=\"_blank\" id=\"12692621\">12692621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleming AB and Saltzman WM, &ldquo;Pharmacokinetics of the Carmustine Implant,&rdquo; <i>Clin Pharmacokinet</i>, 2002, 41(6):403-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/12074689/pubmed\" target=\"_blank\" id=\"12074689\">12074689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gliadel (carmustine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20637881\"></a>Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962. <i>Biol Blood Marrow Transplant</i>. 2011;17(2):249-258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20637881/pubmed\" target=\"_blank\" id=\"20637881\">20637881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim JE, Lee DH, Yoo C, et al, &ldquo;BEAM or BuCyE High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients: A Single Center Comparative Analysis of Efficacy and Toxicity,&rdquo; <i>Leuk Res</i>, 2011, 35(2):183-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20684990/pubmed\" target=\"_blank\" id=\"20684990\">20684990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &quot;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&quot; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA, Leong T, Li S, et al, &ldquo;Complete Response in Multiple Myeloma: Clinical Trial E9486, an Eastern Cooperative Oncology Group Study Not Involving Stem Cell Transplantation,&rdquo; <i>Cancer</i>, 2006, 106(9):1958-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/16565956/pubmed\" target=\"_blank\" id=\"16565956\">16565956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20201949\"></a>Linch DC, Yung L, Smith P, et al, &ldquo;Final Analysis of the UKLG LY02 Trial Comparing 6-8 Cycles of CHOP With 3 Cycles of CHOP Followed by a BEAM Autograft in Patients &lt;65 Years With Poor Prognosis Histologically Aggressive NHL,&rdquo; <i>Br J Haematol</i>, 2010, 149(2):237-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/20201949/pubmed\" target=\"_blank\" id=\"20201949\">20201949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahendra P, Johnson D, Scott MA, et al, &ldquo;Peripheral Blood Progenitor Cell Transplantation: A Single Centre Experience Comparing Two Mobilisation Regimens in 67 Patients,&rdquo; <i>Bone Marrow Transplant</i>, 1996, 17(4):503-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/8722346/pubmed\" target=\"_blank\" id=\"8722346\">8722346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute;n A, Fern&aacute;ndez-Jim&eacute;nez MC, Caballero MD, et al, &ldquo;Long-Term Follow-Up in Patients Treated With Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease,&rdquo; <i>Br J Haematol</i>, 2001, 113(1):161-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/11328296/pubmed\" target=\"_blank\" id=\"11328296\">11328296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7884420\"></a>Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 1995;13(3):588-595.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/7884420/pubmed\" target=\"_blank\" id=\"7884420\">7884420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oken MM, Harrington DP, Abramson N, et al, &ldquo;Comparison of Melphalan and Prednisone With Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Multiple Myeloma: Results of Eastern Cooperative Oncology Group Study E2479,&rdquo; <i>Cancer</i>, 1997, 79(8):1561-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/9118039 /pubmed\" target=\"_blank\" id=\"9118039 \">9118039 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1919637\"></a>Reece DE, Barnett MJ, Connors JM, et al, &ldquo;Intensive Chemotherapy With Cyclophosphamide, Carmustine, and Etoposide Followed by Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease,&rdquo; <i>J Clin Oncol</i>, 1991, 9(10):1871-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/1919637/pubmed\" target=\"_blank\" id=\"1919637\">1919637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Selker RG, Shapiro WR, Burger P, et al, &ldquo;The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine Versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine,&rdquo; <i>Neurosurgery</i>, 2002, 51(2):343-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/12182772/pubmed\" target=\"_blank\" id=\"12182772\">12182772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Xu QA, and Baker M, &ldquo;Drug Compatibility With New Polyolefin Infusion Solution Containers,&rdquo; <i>Am J Health-Syst Pharm</i>, 2006, 63(23):2379-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/17106012/pubmed\" target=\"_blank\" id=\"17106012\">17106012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weingart JD and Brem H, &ldquo;Carmustine Implants: Potential in the Treatment of Brain Tumors,&rdquo; <i>CNS Drugs</i>, 1996, 4:263-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14686972\"></a>Zackheim HS, &ldquo;Topical Carmustine (BCNU) in the Treatment of Mycosis Fungoides,&rdquo; <i>Dermatol Ther</i>, 2003,16(4):299-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carmustine-drug-information/abstract-text/14686972/pubmed\" target=\"_blank\" id=\"14686972\">14686972</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9206 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708652\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F146512\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146513\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F146552\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F146516\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50023578\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F146517\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4426174\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F146518\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344387\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F12855270\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146489\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F146473\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F146492\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130925\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F146490\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722051\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2136823\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146481\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146495\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146477\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298978\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146483\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F146485\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F146498\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F146499\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F146487\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146476\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F146494\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5100296\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146500\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9206|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carmustine-patient-drug-information\" class=\"drug drug_patient\">Carmustine: Patient drug information</a></li><li><a href=\"topic.htm?path=carmustine-pediatric-drug-information\" class=\"drug drug_pediatric\">Carmustine: Pediatric drug information</a></li></ul></div></div>","javascript":null}